Article Text

PDF
DI-005 Use of belimumab for the treatment of systemic lupus erythematosus in a tertiary level hospital
  1. V Alonso Castro,
  2. C Gonzalez Martin,
  3. A Sanchez Guerrero,
  4. A Torralba Arranz
  1. Hospital Universitario Puerta de Hierro Majadahonda, Farmacia Hospitalaria, Majadahonda (Madrid), Spain

Abstract

Background Benlysta is a human monoclonal antibody that is indicated as add-on treatment in adult patients with active, autoantibody-positive (antinuclear antibodies ANA ≥ 1/80) systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard treatment.

Purpose To investigate the benefit of use of belimumab for the treatment of SLE in a tertiary care hospital.

Materials and methods A retrospective observational study of patients undergoing belimumab treatment between January 2012 and July 2013. The following data were reviewed from Selene (medical history software): sex; age; dose; ANA and complement levels; articular, cutaneous, haematological or other conditions; concomitant treatments; adverse reactions; suspension and cause.

Results 6 patients with active SLE (100% with ANA ≥ 1/80) were treated with belimumab (average age 38, 100% women) with a standard dose of 10 mg/kg. All revealed articular involvement, five cutaneous involvement, 2 haematological involvement, and 2 renal involvement (lupus nephritis).

All patients were on a stable SLE treatment regimen consisting of (alone or in combination): corticosteroids (prednisone), anti-malarials (hydroxychloroquine) or immunosuppressive (mycophenolate mofetil).

The most common adverse reactions were: asthenia (4 patients), lymphopenia (2), neutropenia (2), anaemia (1), cutaneous recurrences (3), nausea (3), infections (cystitis (2), respiratory infection (1)), arthralgia (1).

50% had to discontinue treatment due to lack of response (2) or prolonged adverse reactions (neutropenia) (1).

Conclusions Belimumab is a recently launched drug which may be useful as an add-on treatment for those patients with active SLE. 50% of patients treated with belimumab revealed sustained improvement in SLE disease activity, with less fatigue, arthralgia and cutaneous exacerbations than that which they had under standard treatment.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.